Abstract
Introduction: This study aimed to investigate the application value of “time in ranges (TIRs)” in dialysis patients with diabetes and summarize the experience of optimizing glycemic control by flash glucose monitoring (FGM) system. Methods: In this monocentric 2-week pilot study, FGM was applied for 14 days in 57 type 2 diabetes mellitus medically stable patients under maintenance hemodialysis to determine their glycemic improvement. The diagnostic value of TIR versus HbA1c in detecting glucose fluctuations and levels was evaluated using receiver operating characteristic analysis. Results: Average glucose exhibited stronger association with TIR (r = −0.785, p < 0.001) than HbA1c (r = 0.644, p < 0.001), and mean amplitude of glycemic excursion (MAGE) had the same conclusion (r = −0.568, p < 0.001 for TIR vs. r = 0.423, p = 0.016 for HbA1c). TIR exhibited a higher area under curve than HbA1c in detecting significant derangements in glucose fluctuation, using a 14-day average FGM-derived coefficient of variation >36% as the reference standard (difference between areas: 0.237; 95% CI 0.092–0.383, p = 0.001). We found a significant improvement in TIR (58.38 ± 19.42 vs. 46.45 ± 24.42 mmol/L, p < 0.001) and a significant decline in MAGE (median 5.64 vs.7.42 mmol/L, p < 0.001) compared to the baseline without deterioration of time spent in hypoglycemia. Conclusion: TIR seems to be feasible and clinically useful for AGP analysis in dialysis patients with diabetes, and FGM can be used to improve glycemic control.
References
1.
Collins
AJ
, Foley
RN
, Herzog
C
, Chavers
BM
, Gilbertson
D
, Ishani
A
, Excerpts from the US renal data system 2009 annual data report
. Am J Kidney Dis
. 2010
;55
(1 Suppl 1
):S1
–7
. .2.
Saran
R
, Li
Y
, Robinson
B
, Ayanian
J
, Balkrishnan
R
, Bragg-Gresham
J
, US renal data system 2014 Aanual data report: epidemiology of kidney disease in the United States
. Am J Kidney Dis
. 2015
;66
(1 Suppl 1
):Svii
–305
. .3.
Go
AS
, Chertow
GM
, Fan
D
, McCulloch
CE
, Hsu
CY
. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
. N Engl J Med
. 2004
;351
(13
):1296
–305
. .4.
Ricks
J
, Molnar
MZ
, Kovesdy
CP
, Shah
A
, Nissenson
AR
, Williams
M
, Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study
. Diabetes
. 2012
;61
(3
):708
–15
. .5.
Umpierrez
GE
, Isaacs
SD
, Bazargan
N
, You
X
, Thaler
LM
, Kitabchi
AE
. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
. J Clin Endocrinol Metab
. 2002
;87
(3
):978
–82
. .6.
Ng
JM
, Cox
H
, Longbotham
D
, Kilpatrick
ES
, Atkin
SL
, Allan
BJ
. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward: response to Turchin et al
. Diabetes Care
. 2009
;32
(12
):e151
; author reply e152. .7.
Holman
RR
, Paul
SK
, Bethel
MA
, Matthews
DR
, Neil
HA
. 10-year follow-up of intensive glucose control in type 2 diabetes
. N Engl J Med
. 2008
;359
(15
):1577
–89
. .8.
Matoba
K
, Hayashi
A
, Shimizu
N
, Moriguchi
I
, Kobayashi
N
, Shichiri
M
. Comparison of accuracy between flash glucose monitoring and continuous glucose monitoring in patients with type 2 diabetes mellitus undergoing hemodialysis
. J Diabetes Complications
. 2020
;34
(11
):107680
. .9.
Haak
T
, Hanaire
H
, Ajjan
R
, Hermanns
N
, Riveline
JP
, Rayman
G
. Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes
. Diabetes Ther
. 2017
;8
(3
):573
–86
. .10.
Battelino
T
, Danne
T
, Bergenstal
RM
, Amiel
SA
, Beck
R
, Biester
T
, Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range
. Diabetes Care
. 2019
;42
(8
):1593
–603
. .11.
Kovatchev
BP
. Metrics for glycaemic control: from HbA
. Nat Rev Endocrinol
. 2017
;13
(7
):425
–36
. .12.
Monnier
L
, Colette
C
, Wojtusciszyn
A
, Dejager
S
, Renard
E
, Molinari
N
, Toward defining the threshold between low and high glucose variability in diabetes
. Diabetes Care
. 2017
;40
(7
):832
–8
. .13.
Kovesdy
CP
, Park
JC
, Kalantar-Zadeh
K
. Glycemic control and burnt-out diabetes in ESRD
. Semin Dial
. 2010
;23
(2
):148
–56
. .14.
Feneberg
R
, Sparber
M
, Veldhuis
JD
, Mehls
O
, Ritz
E
, Schaefer
F
. Altered temporal organization of plasma insulin oscillations in chronic renal failure
. J Clin Endocrinol Metab
. 2002
;87
(5
):1965
–73
. .15.
Coelho
S
. What is the role of HbA1c in diabetic hemodialysis patients
. Semin Dial
. 2016
;29
(1
):19
–23
. .16.
Chamberlain
JJ
, Doyle-Delgado
K
, Peterson
L
, Skolnik
N
. Diabetes technology: review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes
. Ann Intern Med
. 2019
;171
(6
):415
–20
.17.
Beck
RW
, Bergenstal
RM
, Riddlesworth
TD
, Kollman
C
, Li
Z
, Brown
AS
, Validation of time in range as an outcome measure for diabetes clinical trials
. Diabetes Care
. 2019
;42
(3
):400
–5
. .18.
Lu
J
, Ma
X
, Zhou
J
, Zhang
L
, Mo
Y
, Ying
L
, Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes
. Diabetes Care
. 2018
;41
(11
):2370
–6
. .19.
Jin
YP
, Su
XF
, Yin
GP
, Xu
XH
, Lou
JZ
, Chen
JJ
, Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy
. J Diabetes Complications
. 2015
;29
(3
):395
–9
. .20.
Jung
HS
, Kim
HI
, Kim
MJ
, Yoon
JW
, Ahn
HY
, Cho
YM
, Analysis of hemodialysis-associated hypoglycemia in patients with type 2 diabetes using a continuous glucose monitoring system
. Diabetes Technol Ther
. 2010
;12
(10
):801
–7
. .21.
Abe
M
, Kalantar-Zadeh
K
. Haemodialysis-induced hypoglycaemia and glycaemic disarrays
. Nat Rev Nephrol
. 2015
;11
(5
):302
–13
. .22.
De Feo
P
, Gallai
V
, Mazzotta
G
, Crispino
G
, Torlone
E
, Perriello
G
, Modest decrements in plasma glucose concentration cause early impairment in cognitive function and later activation of glucose counterregulation in the absence of hypoglycemic symptoms in normal man
. J Clin Invest
. 1988
;82
(2
):436
–44
. .23.
Abe
M
, Kaizu
K
, Matsumoto
K
. Evaluation of the hemodialysis-induced changes in plasma glucose and insulin concentrations in diabetic patients: comparison between the hemodialysis and non-hemodialysis days
. Ther Apher Dial
. 2007
;11
(4
):288
–95
. .24.
Gianchandani
RY
, Neupane
S
, Iyengar
JJ
, Heung
M
. Pathophysiology and management of hypoglycemiain end-stage renal disease patients: a review
. Endocr Pract
. 2017
;23
(3
):353
–62
. .25.
Joubert
M
, Fourmy
C
, Henri
P
, Ficheux
M
, Lobbedez
T
, Reznik
Y
. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study
. Diabetes Res Clin Pract
. 2015
;107
(3
):348
–54
. .26.
Bolinder
J
, Antuna
R
, Geelhoed-Duijvestijn
P
, Kröger
J
, Weitgasser
R
. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial
. Lancet
. 2016
;388
:2254
–63
. .27.
Jangam
S
, Dunn
T
, Xu
Y
, Hayter
G
, Ajjan
RA
. Flash glucose monitoring improves glycemia in higher risk patients: a longitudinal, observational study under real-life settings
. BMJ Open Diabetes Res Care
. 2019
;7
(1
):e000611
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
